Thomas Fremming Dejgaard

16PUBLICATIONS
51CO-AUTHORS
PharmacogenomicsGene expression (incl. microarray and other genome-wide approaches)Nutrigenomics and personalised nutritionCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 09, 2026
Additive Glucagonotropic and Insulinotropic Effects of Glucose-Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men.

|May 05, 2026
The Glucagonotropic Effect of GIP Is Negated During Insulin-Induced Hypoglycemia in Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.

|Dec 29, 2025
Glucose-dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes-A randomised placebo-controlled study.

Bjørn Hoe, Sebastian M N Heimbürger, Lærke S Gasbjerg

|Oct 06, 2025
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial.

David S Mathiesen, Josefine V Hansen, Aske Høck

|Jul 29, 2025
The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.

Elisabeth B Stougaard, Mads R Andersen, Jonatan I Bagger

|Aug 28, 2024
Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.

Thomas F Dejgaard, Christian S Frandsen, Urd Kielgast

Pageof 3

Frequent Collaborators

7 joint publications

Jens Juul Holst

6 joint publications

Filip Krag Knop

3 joint publications

Lærke S Gasbjerg

3 joint publications

Sten Madsbad